PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
News|Articles|September 11, 2020
Tjoapack to Invest in Automated Injectables Packaging Capabilities
Author(s)Pharmaceutical Technology Editors
Tjoapack is investing in fully automated lines, including a PFS line with an initial capacity of 7 million syringes per year and a vial line with an eventual capacity of more than 12 million vials per year.
Advertisement
Tjoapack, a contract packaging organization, announced on Sept. 10, 2020 that it is investing in automated injectables packaging capabilities to meet customer demands for prefilled syringes (PFS) and vials.
A new, fully automated PFS line features an initial capacity of 7 million syringes per year and has the ability to assemble, automate insertion of plunger rods and back-stops, carry out inline labelling, and complete coding and vision control, a company press release said. It will be fully operational by the fourth quarter of 2021. A fully automated vial line will begin operations in the first quarter of 2021 and will increase its capacity to over 12 million vials per year.
“As new therapies emerge to address unmet patient needs for chronic ailments the demand for contract packaging organization[s] that can handle syringes and vials will continue to rise,” said Dexter Tjoa, CEO, Tjoapack, in the press release. “Technological advancements, improving patient compliance, beneficial reimbursement policies, and the rise of biologics in the pharmaceutical market will also further propel the needs for service providers who can meet these requirements.”
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Advertisement
Advertisement